In collaboration with Exact Sciences, Baylor Scott & White Research Institute are now enrolling its first patients in the Texas Multi-Cancer Early Detection (MCED) Registry.
The study results show exciting immune responses in patients with operable esophageal or gastroesophageal cancers given neoadjuvant immunotherapy and highlight the potential for monitoring circulating tumor DNA as a predictor for future intervention.
After more than 18 months of working to meet the criteria to become an authorized treatment center,
Baylor University Medical Center is poised to be one of the first in the nation to offer a newly FDA-approved tumor-infiltrating lymphocytes (TIL) cellula
...
Baylor Scott & White Glenda Tanner Vasicek Cancer Treatment Center (VCTC) – Temple opened a new radiation oncology facility that will benefit Central Texas cancer patients. Located on the Baylor Scott & White Medical Center – Temple campus, the two-story 2
...
Once again, Baylor Scott & White is the most awarded not-for-profit health system in Texas with a total of 27 medical centers—more than ever before—recognized on U.S. News & World Report 2021-2022 “Best Hospitals” list. Two of the System’s flagship academi
...
A major advancement for cancer patients has happened today, stemming from clinical research that was conducted right here in Dallas. Dr. Ronan Kelly explains what patients need to know about the significance of the FDA’s approval of nivolumab.
In mid-October, Baylor Scott & White Medical Center – Temple conducted its 1000th holmium laser enucleation of the prostate (HoLEP), a minimally invasive procedure that can address benign prostatic hyperplasia (BPH).
Baylor Scott & White Health today announced a major research advancement in the treatment of esophageal (E) and gastroesophageal junction (GEJ) cancers
